MedPath

Carboplatin

Generic Name
Carboplatin
Brand Names
Paraplatin
Drug Type
Small Molecule
Chemical Formula
C6H12N2O4Pt
CAS Number
41575-94-4
Unique Ingredient Identifier
BG3F62OND5
Background

Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication

Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions
Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy

Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma

Phase 2
Completed
Conditions
Lymphoma
First Posted Date
2003-01-27
Last Posted Date
2023-12-27
Lead Sponsor
University of Nebraska
Registration Number
NCT00007865
Locations
🇺🇸

University of Nebraska Medical Center, Eppley Cancer Center, Omaha, Nebraska, United States

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer

Phase 1
Completed
Conditions
Cancer
Interventions
Biological: filgrastim
Drug: carboplatin
Drug: cisplatin
Drug: cyclophosphamide
Drug: etoposide
Drug: ifosfamide
Drug: mesna
Drug: paclitaxel
Procedure: peripheral blood stem cell transplantation
First Posted Date
2003-01-27
Last Posted Date
2015-08-26
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
33
Registration Number
NCT00002854
Locations
🇺🇸

City of Hope Comprehensive Cancer Center, Duarte, California, United States

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor

Phase 2
Withdrawn
Conditions
Retinoblastoma
Brain and Central Nervous System Tumors
Neuroblastoma
Sarcoma
First Posted Date
2003-01-27
Last Posted Date
2015-12-03
Lead Sponsor
NYU Langone Health
Registration Number
NCT00003273
Locations
🇺🇸

Cancer Research Center of Hawaii, Honolulu, Hawaii, United States

🇺🇸

State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States

🇺🇸

Maine Children's Cancer Program, Scarborough, Maine, United States

and more 16 locations

Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors

Phase 2
Completed
Conditions
Childhood Germ Cell Tumor
Brain Tumor
Central Nervous System Tumors
Interventions
Drug: carboplatin
Drug: etoposide
Drug: ifosfamide
Drug: thiotepa
Procedure: adjuvant therapy
Procedure: conventional surgery
Procedure: neoadjuvant therapy
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy
First Posted Date
2003-01-27
Last Posted Date
2018-02-14
Lead Sponsor
Children's Oncology Group
Target Recruit Count
104
Registration Number
NCT00047320
Locations
🇺🇸

Childrens Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

Children's National Medical Center, Washington, District of Columbia, United States

🇺🇸

Nemours Children's Clinic, Jacksonville, Florida, United States

and more 102 locations

Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Phase 2
Completed
Conditions
Lung Cancer
Interventions
First Posted Date
2003-01-27
Last Posted Date
2016-07-19
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
69
Registration Number
NCT00033553
Locations
🇺🇸

Lombardi Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States

🇺🇸

Walter Reed Army Medical Center, Washington, District of Columbia, United States

🇺🇸

Veterans Affairs Medical Center - Washington, DC, Washington, District of Columbia, United States

and more 71 locations

Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer

Phase 2
Completed
Conditions
Prostate Cancer
Interventions
First Posted Date
2003-01-27
Last Posted Date
2016-07-06
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
34
Registration Number
NCT00016913
Locations
🇺🇸

Walter Reed Army Medical Center, Washington, District of Columbia, United States

🇺🇸

Bon Secours St. Francis Health System, Greenville, South Carolina, United States

🇺🇸

CCOP - Greenville, Greenville, South Carolina, United States

and more 20 locations

Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2
Completed
Conditions
Lung Cancer
First Posted Date
2003-01-27
Last Posted Date
2021-09-09
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
14
Registration Number
NCT00025272
Locations
🇺🇸

CCOP - Upstate Carolina, Spartanburg, South Carolina, United States

🇺🇸

Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States

🇺🇸

Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States

and more 2 locations

Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

Phase 2
Completed
Conditions
Lymphoma
Interventions
Biological: filgrastim
Drug: carboplatin
Drug: carmustine
Drug: cyclophosphamide
Drug: cytarabine
Drug: etoposide
Drug: ifosfamide
Drug: melphalan
Procedure: bone marrow ablation with stem cell support
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy
First Posted Date
2003-01-27
Last Posted Date
2016-01-25
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
118
Registration Number
NCT00003631
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer

Phase 2
Completed
Conditions
Peritoneal Cavity Cancer
Ovarian Cancer
Fallopian Tube Cancer
Interventions
Drug: carboplatin
Drug: paclitaxel
Procedure: debulking surgery
First Posted Date
2003-01-27
Last Posted Date
2016-01-08
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
62
Registration Number
NCT00008138

Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2
Completed
Conditions
Prostate Cancer
Interventions
First Posted Date
2003-01-27
Last Posted Date
2020-09-01
Lead Sponsor
Jonsson Comprehensive Cancer Center
Target Recruit Count
58
Registration Number
NCT00049257
Locations
🇺🇸

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath